Vaxart Announces Special Meeting Adjournment
Vaxart, Inc. (NASDAQ: VXRT), a pioneering biotechnology company, has announced the adjournment of its special meeting of stockholders. This decision provides additional time for stockholders to consider pivotal proposals that could shape the company's future.
Details of the Adjournment
The special meeting, originally scheduled for September 5, will now take place on September 19, 2025, at 8:30 a.m. Pacific Time. Vaxart is committed to ensuring that all stockholders have ample opportunity to participate in the decision-making process, especially in light of recent changes in the Board’s composition and other governance matters.
Importance of Stockholder Participation
Vaxart encourages all stockholders of record by July 29, 2025, who have yet to vote, to submit their votes by September 18, 2025, at 11:59 p.m. Eastern Time. This is a crucial moment as stockholders can influence significant proposals, including discussions around a reverse stock split.
Engagement and Future Expectations
Steven Lo, CEO of Vaxart, expressed that maintaining a listing on Nasdaq is vital for advancing their scientific efforts while maximizing stockholder value. The leadership is eager to engage in conversations with stockholders leading up to the adjourned meeting, highlighting the importance of their feedback in shaping the company's strategy.
Proxy Voting and Future Proposals
The company indicates that proxies submitted prior to the adjournment will still be valid and will be used to vote on applicable proposals at the new meeting date unless revoked properly. This stipulation ensures that prior efforts by stockholders are still recognized, fostering a sense of continuity in the governance process.
Vaxart’s Cutting-Edge Technologies
At the forefront of innovation, Vaxart specializes in oral recombinant vaccines developed using their proprietary delivery platform. This technology offers a promising alternative by enabling vaccines to be administered in pill form—an advancement that eliminates the cold storage requirement and the risk associated with needle stick injuries.
Current Vaccine Development Programs
Vaxart’s current pipeline includes vaccines targeting several viruses, including coronavirus, norovirus, and influenza. Furthermore, they are developing a therapeutic vaccine for human papillomavirus (HPV), marking the company's venture into immune-oncology, which may enhance treatment outcomes for various cancers.
Given the changing landscape of vaccine technology and delivery systems, Vaxart’s commitment to developing effective oral vaccines may position them favorably in the biotechnology sector.
Contact and Proxy Assistance
If stockholders have questions or need assistance regarding their voting rights, Vaxart recommends reaching out to their proxy solicitation firm, Campaign Management, LLC, by calling 1-855-264-1527 or emailing info@campaign-mgmt.com. This support ensures that stockholders feel informed and empowered to exercise their voting rights during this critical time.
Frequently Asked Questions
What is the new date for Vaxart's special meeting?
The special meeting has been adjourned to September 19, 2025, at 8:30 a.m. Pacific Time.
Why was the meeting adjourned?
The adjournment provides stockholders with more time to consider and vote on important proposals in light of recent governance changes.
How can stockholders participate in the vote?
Stockholders should vote by September 18, 2025, at 11:59 p.m. Eastern Time to have their voices heard on pivotal proposals.
What is Vaxart's focus in vaccine development?
Vaxart is focused on developing oral recombinant vaccines that aim to prevent diseases such as COVID-19, influenza, and HPV.
Who can stockholders contact for further information?
Stockholders can contact Vaxart’s proxy solicitation firm, Campaign Management, LLC, for assistance with voting and inquiries.
